Liquid Biopsy Market was valued at US$ 2.11 Bn. in 2022. Global Liquid Biopsy Market size is expected to grow at a CAGR of 20.9 % through the forecast period.Liquid Biopsy Market Overview:
Liquid biopsy is an easy, quick, non-invasive, and repeatable sampling technique that can reflect changes in tumor gene expression profiles and offer a solid foundation for customized treatment and cancer early detection. The focus in recent years has also been on early cancer detection, tracking the development of tumors, evaluating therapy response and clinical prognosis, and identifying recurrent and refractory cancers.To know about the Research Methodology:-Request Free Sample Report Furthermore, due to technological advancements in both practicality and turnaround time, liquid biopsy has recently attracted a lot of attention as a non-invasive substitute procedure for tissue biopsy in patients with cancer. 2022 is considered as a base year to forecast the market from 2023 to 2029. 2022’s market size is estimated on real numbers and outputs of the key players and major players across the globe. Past five years' trends are considered while forecasting the market through 2029. 2022 is a year of exception and analysis especially with the impact of lockdown by region.
Liquid Biopsy Market Dynamics:
Liquid Biopsy Market COVID 19 Insights: Although COVID-19's far-reaching consequences have been unprecedented, cancer sufferers have been among the most severely impacted groups. The number of patients getting cancer screening, diagnosis, and treatment has been significantly impacted by COVID-19. Oncology clinics were re-profiled for treating patients with the COVID-19 as a result of the increasing demand brought on by the rising rate of COVID-19 patients being hospitalized. As a result, a study found that numerous diagnostic and therapeutic operations, including up to 2.3 million cancer surgeries, have been shelved or delayed world. However, as nations gradually loosen their travel restrictions, testing numbers are expected to increase again. Responding to rising cancer incidence has become a critical medical concern on a global scale since the COVID-19 pandemic. Cancer has been recognized as a risk factor for COVID-19 because several COVID-19 patients had malignancies. It is expected that additional research in this area would advance cancer research by helping to better understand the dynamics of infection. It is also expected that this will increase demand for liquid biopsy products. Liquid Biopsy Market Drivers: Rising incidence and prevalence of cancer: The number of persons who have cancer has significantly increased on a world basis. Environmental factors, cigarette use, infectious diseases like Hepatitis B and C, as well as lifestyle changes, are some of the causes of the increased incidence of cancer. Cancer is the second-leading cause of mortality worldwide, according to the WHO. According to estimates from the International Agency for Research on Cancer (IARC), there would be 19.3 million new cases of cancer and 9.96 million cancer-related deaths worldwide in 2022. Compared to conventional cancer diagnostic methods, liquid biopsy has various advantages, including lower cost, early prognosis, therapy monitoring, tumor heterogeneity identification, acquired drug resistance, and patient comfort (by eliminating the need for surgery). As a result, the liquid biopsy will probably become more popular. Liquid Biopsy Market Restraints: The lower sensitivity of certain liquid biopsies: The quantities of ctDNA of any particular cancer mutation may be very low in the plasma of a cancer patient, especially after treatment or surgery, making the detection of ctDNA in liquid biopsies technically tricky. According to sampling statistics, there may be less than one detectable copy of the cancer mutation-containing ctDNA in any one patient's plasma sample. As a result, even though ctDNA is present in the plasma but at a low level, it might not be picked up in the patient sample. This affects the informative value of the liquid biopsy tests for cancer by producing false-negative results where ctDNA is present but not identified. False negatives can occasionally result in a tumor's recurrence not being discovered at an early stage. Liquid Biopsy Market Opportunities: The growing significance of companion diagnostics: Companion diagnostics are tests or assays used to help doctors decide what course of treatment to provide patients based on how well they respond to therapy. The rapid and cost-effective production of safer pharmaceuticals with improved therapeutic efficacy can fundamentally modify the drug development process and accelerate the commercialization of medication candidates. The market for companion diagnostics has significant growth potential due to the rise in demand for expensive specialized therapies and safer medications. The market for liquid biopsies is seeing prospects for growth as companion diagnostics gain prominence. Liquid Biopsy Market Challenges: Unclear reimbursement scenario: The procedure of paying for pricey molecular testing and the knowledge of the several specialists needed to interpret test results and create treatment programs are convoluted and uneven. This is particularly problematic with more expensive modern methods like liquid biopsy. The price of molecular testing services is frequently unknown to doctors, pathologists, and patients until they are paid or billed. Both patients and medical professionals find the confusion disturbing. Additionally, payers' biomarker coverage policies have complex organizational structures that make them challenging to comprehend. While some only pay for the most fundamental tests or those related to certain clinical disorders and genes, others pay for a wide variety of testing. It is frequently more difficult to evaluate and keep track of different coverage policies due to this significant variety.Liquid Biopsy Market Segment Analysis:
Based on Technology, In terms of revenue, the Multi-gene-parallel Analysis (NGS) category accounted for over 73 % of the global market in 2022, and it is expected that it will continue to dominate over the forecast period. NGS technology may identify a wide range of mutations that might contribute to carcinogenesis as well as identify potential resistance mechanisms that might have emerged from pre-existing clones following therapy. Recent rapid advancements in NGS technology have resulted in a significant cost reduction for high-accuracy sequencing. This approach enables the screening of unidentified variations and is employed in focused panels for the precise and extremely sensitive detection of ctDNA mutations. For instance, stage 1 or stage 2 lung cancer patients can be identified by NGS with a MAF of roughly 0.1%. Important operational companies have also released cutting-edge products, driving the market. For instance, Twist Bioscience Corp. introduced the Twist NGS Methylation Detection System in February 2021 for epigenetic research and liquid biopsy cancer analysis. Additionally, Biodesix, Inc. announced in April 2021 that it would expand its line of molecular testing by introducing a blood-based 52-gene NGS test. Based on the Biomarker, The circulating Nucleic Acids Segment is dominating the market with a 36.67% share. The section is driven by the numerous uses of circulating tumor DNA (ctDNA) in liquid biopsies of cancer. Recent advancements in ctDNA-based liquid biopsy analysis have opened up new possibilities for cancer molecular diagnosis and surveillance. It can accurately predict tumour development, the prognosis, and help with targeted therapy.Liquid biopsies are being used by translational cancer researchers to identify ctDNA from tumours. Future liquid biopsy applications for cancer detection have a significant chance to use the detection of ctDNA as a possible biomarker. ctDNA has been made available as an alternate source to invasive methods for molecular profiling of tumour DNA in cancer patients. The fastest CAGR is expected for Exosomes/Microvesicles through the forecast period. Exosomes are being more widely used as liquid biopsies in oncology clinical diagnostics, and the arrival of novel products also contributes to the segment's growth. At the American Urological Association's (AUA) 2022 Annual Meeting, miR Scientific presented findings for its miR Sentinel Prostate Cancer Test in September of that year. A single urine sample is used in this exosome-based liquid biopsy test, which has a 90% accuracy rate for detecting prostate cancer.
Regional Insights:
The North America region is dominating the liquid biopsy market with a 51% share. Due to higher investments and the existence of numerous biotechnology businesses producing the tests, the U.S. dominates the regional market. Liquid biopsy is supported by several organizations, including the American Society of Clinical Oncology (ASCO). In consequence, it is expected that this will accelerate sales growth in this area. Since tests that have received FDA approval may be utilized there, Canada has followed the United States in adopting liquid biopsy procedures. Additionally, the industry is highly competitive, which is expected to fuel sales growth throughout the forecast period. a rise in government funding and investments for the creation of liquid biopsy testing. For instance, BioMark Diagnostic Solutions, Inc. received USD 825,000 in financing in June 2021 to develop the liquid biopsy assay for lung cancer screening. Consortium for Industrial Research and Innovation in Medical Technology grants and Spark funds from the Canadian Cancer Society, Brain Canada Foundation, and Canadian Institutes of Health Research - Institute of Cancer Research provide a sizable portion of the funding. The objective of the report is to present a comprehensive analysis of the global Liquid Biopsy Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The reports also help in understanding the Liquid Biopsy Market dynamic, structure by analyzing the market segments and projecting the Liquid Biopsy Market size. Clear representation of competitive analysis of key players by Product type, price, financial position, product portfolio, growth strategies, and regional presence in the Liquid Biopsy Market make the report investor’s guide.Liquid Biopsy Market Scope: Inquire before buying
Global Liquid Biopsy Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2018 to 2022 Market Size in 2022: US$ 2.11 Bn. Forecast Period 2023 to 2029 CAGR: 20.9% Market Size in 2029: US$ 8 Bn. Segments Covered: by Product Assay Kits Instruments by Technology Multi-gene-parallel Analysis (NGS) Single Gene Analysis (PCR Microarrays) by Application Cancer Non- Cancer by End User Reference Lab Hospitals Liquid Biopsy Market by Region
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) North America (United States, Canada and Mexico) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Key Players
1. F. Hoffmann-La Roche Ltd. (Switzerland) 2. Myriad Genetics, Inc. (US) 3. QIAGEN N.V. (Netherlands) 4. Thermo Fisher Scientific, Inc. (US) 5. Guardant Health, Inc. (US) 6. MDxHealth SA (Belgium) 7. Exact Sciences Corporation (US) 8. Illumina Inc. (US) 9. Sysmex Inostics (US) 10. Bio-Rad Laboratories, Inc. (US) 11. Biocept, Inc. (US) 12. NeoGenomics, Inc. (US) 13. ANGLE plc. (UK) 14. Menarini-Silicon Biosystems (Italy) 15. Vortex Biosciences, Inc. (US) 16. Exosome Diagnostics, Inc. (US) 17. Agena Bioscience, Inc. (US) 18. MedGenome Inc. (US) 19. Epigenomics AG (Germany) 20. Personal Genome Diagnostics, Inc. (US). Frequently Asked Questions: 1] What segments are covered in the Global Liquid Biopsy Market report? Ans. The segments covered in the Liquid Biopsy Market report are based on Technology, Biomarker, and Sample Type. 2] Which region is expected to hold the highest share in the Global Liquid Biopsy Market? Ans. The North America region is expected to hold the highest share in the Liquid Biopsy Market. 3] What is the market size of the Global Liquid Biopsy Market by 2029? Ans. The market size of the Liquid Biopsy Market by 2029 is expected to reach US$ 8 Bn. 4] What is the forecast period for the Global Liquid Biopsy Market? Ans. The forecast period for the Liquid Biopsy Market is 2023-2029. 5] What was the market size of the Global Liquid Biopsy Market in 2022? Ans. The market size of the Liquid Biopsy Market in 2022 was valued at US$ 2.11 Bn.
1. Liquid Biopsy Market: Research Methodology 2. Liquid Biopsy Market Introduction 2.1. Study Assumption and Market Definition 2.2. Scope of the Study 2.3. Executive Summary 3. Liquid Biopsy Market: Dynamics 3.1. Liquid Biopsy Market Trends by Region 3.1.1. North America Liquid Biopsy Market Trends 3.1.2. Europe Liquid Biopsy Market Trends 3.1.3. Asia Pacific Liquid Biopsy Market Trends 3.1.4. Middle East and Africa Liquid Biopsy Market Trends 3.1.5. South America Liquid Biopsy Market Trends 3.2. Liquid Biopsy Market Dynamics by Region 3.2.1. North America 3.2.1.1. North America Liquid Biopsy Market Drivers 3.2.1.2. North America Liquid Biopsy Market Restraints 3.2.1.3. North America Liquid Biopsy Market Opportunities 3.2.1.4. North America Liquid Biopsy Market Challenges 3.2.2. Europe 3.2.2.1. Europe Liquid Biopsy Market Drivers 3.2.2.2. Europe Liquid Biopsy Market Restraints 3.2.2.3. Europe Liquid Biopsy Market Opportunities 3.2.2.4. Europe Liquid Biopsy Market Challenges 3.2.3. Asia Pacific 3.2.3.1. Asia Pacific Liquid Biopsy Market Drivers 3.2.3.2. Asia Pacific Liquid Biopsy Market Restraints 3.2.3.3. Asia Pacific Liquid Biopsy Market Opportunities 3.2.3.4. Asia Pacific Liquid Biopsy Market Challenges 3.2.4. Middle East and Africa 3.2.4.1. Middle East and Africa Liquid Biopsy Market Drivers 3.2.4.2. Middle East and Africa Liquid Biopsy Market Restraints 3.2.4.3. Middle East and Africa Liquid Biopsy Market Opportunities 3.2.4.4. Middle East and Africa Liquid Biopsy Market Challenges 3.2.5. South America 3.2.5.1. South America Liquid Biopsy Market Drivers 3.2.5.2. South America Liquid Biopsy Market Restraints 3.2.5.3. South America Liquid Biopsy Market Opportunities 3.2.5.4. South America Liquid Biopsy Market Challenges 3.3. PORTER’s Five Forces Analysis 3.4. PESTLE Analysis 3.5. Technology Roadmap 3.6. Regulatory Landscape by Region 3.6.1. North America 3.6.2. Europe 3.6.3. Asia Pacific 3.6.4. Middle East and Africa 3.6.5. South America 3.7. Key Opinion Leader Analysis For the Liquid Biopsy Industry 3.8. Analysis of Government Schemes and Initiatives For Liquid Biopsy Industry 3.9. The Global Pandemic Impact on Liquid Biopsy Market 4. Liquid Biopsy Market: Global Market Size and Forecast by Segmentation by Demand and Supply Side (by Value in USD Million) (2023-2030) 4.1. Liquid Biopsy Market Size and Forecast, by Product (2023-2030) 4.1.1. Assay Kits 4.1.2. Instruments 4.2. Liquid Biopsy Market Size and Forecast, by Technology (2023-2030) 4.2.1. NGS 4.2.2. PCR 4.3. Liquid Biopsy Market Size and Forecast, by Application (2023-2030) 4.3.1. Cancer 4.3.2. Non- Cancer 4.4. Liquid Biopsy Market Size and Forecast, by End User (2023-2030) 4.4.1. Reference Lab 4.4.2. Hospitals 4.5. Liquid Biopsy Market Size and Forecast, by Region (2023-2030) 4.5.1. North America 4.5.2. Europe 4.5.3. Asia Pacific 4.5.4. Middle East and Africa 4.5.5. South America 5. North America Liquid Biopsy Market Size and Forecast by Segmentation by Demand and Supply Side (by Value in USD Million) (2023-2030) 5.1. North America Liquid Biopsy Market Size and Forecast, by Product (2023-2030) 5.1.1. Assay Kits 5.1.2. Instruments 5.2. North America Liquid Biopsy Market Size and Forecast, by Technology (2023-2030) 5.2.1. NGS 5.2.2. PCR 5.3. North America Liquid Biopsy Market Size and Forecast, by Application (2023-2030) 5.3.1. Cancer 5.3.2. Non- Cancer 5.4. North America Liquid Biopsy Market Size and Forecast, by End User (2023-2030) 5.4.1. Reference Lab 5.4.2. Hospitals 5.5. North America Liquid Biopsy Market Size and Forecast, by Country (2023-2030) 5.5.1. United States 5.5.1.1. United States Liquid Biopsy Market Size and Forecast, by Product (2023-2030) 5.5.1.1.1. Assay Kits 5.5.1.1.2. Instruments 5.5.1.2. United States Liquid Biopsy Market Size and Forecast, by Technology (2023-2030) 5.5.1.2.1. NGS 5.5.1.2.2. PCR 5.5.1.3. United States Liquid Biopsy Market Size and Forecast, by Application (2023-2030) 5.5.1.3.1. Cancer 5.5.1.3.2. Non- Cancer 5.5.1.4. United States Liquid Biopsy Market Size and Forecast, by End User (2023-2030) 5.5.1.4.1. Reference Lab 5.5.1.4.2. Hospitals 5.5.2. Canada 5.5.2.1. Canada Liquid Biopsy Market Size and Forecast, by Product (2023-2030) 5.5.2.1.1. Assay Kits 5.5.2.1.2. Instruments 5.5.2.2. Canada Liquid Biopsy Market Size and Forecast, by Technology (2023-2030) 5.5.2.2.1. NGS 5.5.2.2.2. PCR 5.5.2.3. Canada Liquid Biopsy Market Size and Forecast, by Application (2023-2030) 5.5.2.3.1. Cancer 5.5.2.3.2. Non- Cancer 5.5.2.4. Canada Liquid Biopsy Market Size and Forecast, by End User (2023-2030) 5.5.2.4.1. Reference Lab 5.5.2.4.2. Hospitals 5.5.3. Mexico 5.5.3.1. Mexico Liquid Biopsy Market Size and Forecast, by Product (2023-2030) 5.5.3.1.1. Assay Kits 5.5.3.1.2. Instruments 5.5.3.2. Mexico Liquid Biopsy Market Size and Forecast, by Technology (2023-2030) 5.5.3.2.1. NGS 5.5.3.2.2. PCR 5.5.3.3. Mexico Liquid Biopsy Market Size and Forecast, by Application (2023-2030) 5.5.3.3.1. Cancer 5.5.3.3.2. Non- Cancer 5.5.3.4. Mexico Liquid Biopsy Market Size and Forecast, by End User (2023-2030) 5.5.3.4.1. Reference Lab 5.5.3.4.2. Hospitals 6. Europe Liquid Biopsy Market Size and Forecast by Segmentation by Demand and Supply Side (by Value in USD Million) (2023-2030) 6.1. Europe Liquid Biopsy Market Size and Forecast, by Product (2023-2030) 6.2. Europe Liquid Biopsy Market Size and Forecast, by Technology (2023-2030) 6.3. Europe Liquid Biopsy Market Size and Forecast, by Application (2023-2030) 6.4. Europe Liquid Biopsy Market Size and Forecast, by End User (2023-2030) 6.5. Europe Liquid Biopsy Market Size and Forecast, by Country (2023-2030) 6.5.1. United Kingdom 6.5.1.1. United Kingdom Liquid Biopsy Market Size and Forecast, by Product (2023-2030) 6.5.1.2. United Kingdom Liquid Biopsy Market Size and Forecast, by Technology (2023-2030) 6.5.1.3. United Kingdom Liquid Biopsy Market Size and Forecast, by Application (2023-2030) 6.5.1.4. United Kingdom Liquid Biopsy Market Size and Forecast, by End User (2023-2030) 6.5.2. France 6.5.2.1. France Liquid Biopsy Market Size and Forecast, by Product (2023-2030) 6.5.2.2. France Liquid Biopsy Market Size and Forecast, by Technology (2023-2030) 6.5.2.3. France Liquid Biopsy Market Size and Forecast, by Application (2023-2030) 6.5.2.4. France Liquid Biopsy Market Size and Forecast, by End User (2023-2030) 6.5.3. Germany 6.5.3.1. Germany Liquid Biopsy Market Size and Forecast, by Product (2023-2030) 6.5.3.2. Germany Liquid Biopsy Market Size and Forecast, by Technology (2023-2030) 6.5.3.3. Germany Liquid Biopsy Market Size and Forecast, by Application (2023-2030) 6.5.3.4. Germany Liquid Biopsy Market Size and Forecast, by End User (2023-2030) 6.5.4. Italy 6.5.4.1. Italy Liquid Biopsy Market Size and Forecast, by Product (2023-2030) 6.5.4.2. Italy Liquid Biopsy Market Size and Forecast, by Technology (2023-2030) 6.5.4.3. Italy Liquid Biopsy Market Size and Forecast, by Application (2023-2030) 6.5.4.4. Italy Liquid Biopsy Market Size and Forecast, by End User (2023-2030) 6.5.5. Spain 6.5.5.1. Spain Liquid Biopsy Market Size and Forecast, by Product (2023-2030) 6.5.5.2. Spain Liquid Biopsy Market Size and Forecast, by Technology (2023-2030) 6.5.5.3. Spain Liquid Biopsy Market Size and Forecast, by Application (2023-2030) 6.5.5.4. Spain Liquid Biopsy Market Size and Forecast, by End User (2023-2030) 6.5.6. Sweden 6.5.6.1. Sweden Liquid Biopsy Market Size and Forecast, by Product (2023-2030) 6.5.6.2. Sweden Liquid Biopsy Market Size and Forecast, by Technology (2023-2030) 6.5.6.3. Sweden Liquid Biopsy Market Size and Forecast, by Application (2023-2030) 6.5.6.4. Sweden Liquid Biopsy Market Size and Forecast, by End User (2023-2030) 6.5.7. Austria 6.5.7.1. Austria Liquid Biopsy Market Size and Forecast, by Product (2023-2030) 6.5.7.2. Austria Liquid Biopsy Market Size and Forecast, by Technology (2023-2030) 6.5.7.3. Austria Liquid Biopsy Market Size and Forecast, by Application (2023-2030) 6.5.7.4. Austria Liquid Biopsy Market Size and Forecast, by End User (2023-2030) 6.5.8. Rest of Europe 6.5.8.1. Rest of Europe Liquid Biopsy Market Size and Forecast, by Product (2023-2030) 6.5.8.2. Rest of Europe Liquid Biopsy Market Size and Forecast, by Technology (2023-2030) 6.5.8.3. Rest of Europe Liquid Biopsy Market Size and Forecast, by Application (2023-2030) 6.5.8.4. Rest of Europe Liquid Biopsy Market Size and Forecast, by End User (2023-2030) 7. Asia Pacific Liquid Biopsy Market Size and Forecast by Segmentation by Demand and Supply Side (by Value in USD Million) (2023-2030) 7.1. Asia Pacific Liquid Biopsy Market Size and Forecast, by Product (2023-2030) 7.2. Asia Pacific Liquid Biopsy Market Size and Forecast, by Technology (2023-2030) 7.3. Asia Pacific Liquid Biopsy Market Size and Forecast, by Application (2023-2030) 7.4. Asia Pacific Liquid Biopsy Market Size and Forecast, by End User (2023-2030) 7.5. Asia Pacific Liquid Biopsy Market Size and Forecast, by Country (2023-2030) 7.5.1. China 7.5.1.1. China Liquid Biopsy Market Size and Forecast, by Product (2023-2030) 7.5.1.2. China Liquid Biopsy Market Size and Forecast, by Technology (2023-2030) 7.5.1.3. China Liquid Biopsy Market Size and Forecast, by Application (2023-2030) 7.5.1.4. China Liquid Biopsy Market Size and Forecast, by End User (2023-2030) 7.5.2. S Korea 7.5.2.1. S Korea Liquid Biopsy Market Size and Forecast, by Product (2023-2030) 7.5.2.2. S Korea Liquid Biopsy Market Size and Forecast, by Technology (2023-2030) 7.5.2.3. S Korea Liquid Biopsy Market Size and Forecast, by Application (2023-2030) 7.5.2.4. S Korea Liquid Biopsy Market Size and Forecast, by End User (2023-2030) 7.5.3. Japan 7.5.3.1. Japan Liquid Biopsy Market Size and Forecast, by Product (2023-2030) 7.5.3.2. Japan Liquid Biopsy Market Size and Forecast, by Technology (2023-2030) 7.5.3.3. Japan Liquid Biopsy Market Size and Forecast, by Application (2023-2030) 7.5.3.4. Japan Liquid Biopsy Market Size and Forecast, by End User (2023-2030) 7.5.4. India 7.5.4.1. India Liquid Biopsy Market Size and Forecast, by Product (2023-2030) 7.5.4.2. India Liquid Biopsy Market Size and Forecast, by Technology (2023-2030) 7.5.4.3. India Liquid Biopsy Market Size and Forecast, by Application (2023-2030) 7.5.4.4. India Liquid Biopsy Market Size and Forecast, by End User (2023-2030) 7.5.5. Australia 7.5.5.1. Australia Liquid Biopsy Market Size and Forecast, by Product (2023-2030) 7.5.5.2. Australia Liquid Biopsy Market Size and Forecast, by Technology (2023-2030) 7.5.5.3. Australia Liquid Biopsy Market Size and Forecast, by Application (2023-2030) 7.5.5.4. Australia Liquid Biopsy Market Size and Forecast, by End User (2023-2030) 7.5.6. Indonesia 7.5.6.1. Indonesia Liquid Biopsy Market Size and Forecast, by Product (2023-2030) 7.5.6.2. Indonesia Liquid Biopsy Market Size and Forecast, by Technology (2023-2030) 7.5.6.3. Indonesia Liquid Biopsy Market Size and Forecast, by Application (2023-2030) 7.5.6.4. Indonesia Liquid Biopsy Market Size and Forecast, by End User (2023-2030) 7.5.7. Malaysia 7.5.7.1. Malaysia Liquid Biopsy Market Size and Forecast, by Product (2023-2030) 7.5.7.2. Malaysia Liquid Biopsy Market Size and Forecast, by Technology (2023-2030) 7.5.7.3. Malaysia Liquid Biopsy Market Size and Forecast, by Application (2023-2030) 7.5.7.4. Malaysia Liquid Biopsy Market Size and Forecast, by End User (2023-2030) 7.5.8. Vietnam 7.5.8.1. Vietnam Liquid Biopsy Market Size and Forecast, by Product (2023-2030) 7.5.8.2. Vietnam Liquid Biopsy Market Size and Forecast, by Technology (2023-2030) 7.5.8.3. Vietnam Liquid Biopsy Market Size and Forecast, by Application (2023-2030) 7.5.8.4. Vietnam Liquid Biopsy Market Size and Forecast, by End User (2023-2030) 7.5.9. Taiwan 7.5.9.1. Taiwan Liquid Biopsy Market Size and Forecast, by Product (2023-2030) 7.5.9.2. Taiwan Liquid Biopsy Market Size and Forecast, by Technology (2023-2030) 7.5.9.3. Taiwan Liquid Biopsy Market Size and Forecast, by Application (2023-2030) 7.5.9.4. Taiwan Liquid Biopsy Market Size and Forecast, by End User (2023-2030) 7.5.10. Rest of Asia Pacific 7.5.10.1. Rest of Asia Pacific Liquid Biopsy Market Size and Forecast, by Product (2023-2030) 7.5.10.2. Rest of Asia Pacific Liquid Biopsy Market Size and Forecast, by Technology (2023-2030) 7.5.10.3. Rest of Asia Pacific Liquid Biopsy Market Size and Forecast, by Application (2023-2030) 7.5.10.4. Rest of Asia Pacific Liquid Biopsy Market Size and Forecast, by End User (2023-2030) 8. Middle East and Africa Liquid Biopsy Market Size and Forecast by Segmentation by Demand and Supply Side (by Value in USD Million) (2023-2030) 8.1. Middle East and Africa Liquid Biopsy Market Size and Forecast, by Product (2023-2030) 8.2. Middle East and Africa Liquid Biopsy Market Size and Forecast, by Technology (2023-2030) 8.3. Middle East and Africa Liquid Biopsy Market Size and Forecast, by Application (2023-2030) 8.4. Middle East and Africa Liquid Biopsy Market Size and Forecast, by End User (2023-2030) 8.5. Middle East and Africa Liquid Biopsy Market Size and Forecast, by Country (2023-2030) 8.5.1. South Africa 8.5.1.1. South Africa Liquid Biopsy Market Size and Forecast, by Product (2023-2030) 8.5.1.2. South Africa Liquid Biopsy Market Size and Forecast, by Product (2023-2030) 8.5.1.3. South Africa Liquid Biopsy Market Size and Forecast, by Technology (2023-2030) 8.5.1.4. South Africa Liquid Biopsy Market Size and Forecast, by Application (2023-2030) 8.5.1.5. South Africa Liquid Biopsy Market Size and Forecast, by End User (2023-2030) 8.5.2. GCC 8.5.2.1. GCC Liquid Biopsy Market Size and Forecast, by Product (2023-2030) 8.5.2.2. GCC Liquid Biopsy Market Size and Forecast, by Technology (2023-2030) 8.5.2.3. GCC Liquid Biopsy Market Size and Forecast, by Application (2023-2030) 8.5.2.4. GCC Liquid Biopsy Market Size and Forecast, by End User (2023-2030) 8.5.3. Nigeria 8.5.3.1. Nigeria Liquid Biopsy Market Size and Forecast, by Product (2023-2030) 8.5.3.2. Nigeria Liquid Biopsy Market Size and Forecast, by Technology (2023-2030) 8.5.3.3. Nigeria Liquid Biopsy Market Size and Forecast, by Application (2023-2030) 8.5.3.4. Nigeria Liquid Biopsy Market Size and Forecast, by End User (2023-2030) 8.5.4. Rest of ME&A 8.5.4.1. Rest of ME&A Liquid Biopsy Market Size and Forecast, by Product (2023-2030) 8.5.4.2. Rest of ME&A Liquid Biopsy Market Size and Forecast, by Technology (2023-2030) 8.5.4.3. Rest of ME&A Liquid Biopsy Market Size and Forecast, by Application (2023-2030) 8.5.4.4. Rest of ME&A Liquid Biopsy Market Size and Forecast, by End User (2023-2030) 9. South America Liquid Biopsy Market Size and Forecast by Segmentation by Demand and Supply Side (by Value in USD Million) (2023-2030) 9.1. South America Liquid Biopsy Market Size and Forecast, by Product (2023-2030) 9.2. South America Liquid Biopsy Market Size and Forecast, by Technology (2023-2030) 9.3. South America Liquid Biopsy Market Size and Forecast, by Application (2023-2030) 9.4. South America Liquid Biopsy Market Size and Forecast, by End User (2023-2030) 9.5. South America Liquid Biopsy Market Size and Forecast, by Country (2023-2030) 9.5.1. Brazil 9.5.1.1. Brazil Liquid Biopsy Market Size and Forecast, by Product (2023-2030) 9.5.1.2. Brazil Liquid Biopsy Market Size and Forecast, by Technology (2023-2030) 9.5.1.3. Brazil Liquid Biopsy Market Size and Forecast, by Application (2023-2030) 9.5.1.4. 9.5.2. Argentina 9.5.2.1. Argentina Liquid Biopsy Market Size and Forecast, by Product (2023-2030) 9.5.2.2. Argentina Liquid Biopsy Market Size and Forecast, by Technology (2023-2030) 9.5.2.3. Argentina Liquid Biopsy Market Size and Forecast, by Application (2023-2030) 9.5.3. Rest Of South America 9.5.3.1. Rest Of South America Liquid Biopsy Market Size and Forecast, by Product (2023-2030) 9.5.3.2. Rest Of South America Liquid Biopsy Market Size and Forecast, by Technology (2023-2030) 9.5.3.3. Rest Of South America Liquid Biopsy Market Size and Forecast, by Application (2023-2030) 10. Global Liquid Biopsy Market: Competitive Landscape 10.1. MMR Competition Matrix 10.2. Competitive Landscape 10.3. Key Players Benchmarking 10.3.1. Company Name 10.3.2. Service Segment 10.3.3. End-user Segment 10.3.4. Revenue (2023) 10.3.5. Company Locations 10.4. Leading Liquid Biopsy Market Companies, by market capitalization 10.5. Market Structure 10.5.1. Market Leaders 10.5.2. Market Followers 10.5.3. Emerging Players 10.6. Mergers and Acquisitions Details 11. Company Profile: Key Players 11.1. F. Hoffmann-La Roche Ltd. 11.1.1. Company Overview 11.1.2. Business Portfolio 11.1.3. Financial Overview 11.1.4. SWOT Analysis 11.1.5. Strategic Analysis 11.1.6. Details on Partnership 11.1.7. Recent Developments 11.2. F. Hoffmann-La Roche Ltd. 11.3. Myriad Genetics, Inc. 11.4. QIAGEN N.V. 11.5. Thermo Fisher Scientific, Inc. 11.6. Guardant Health, Inc. 11.7. MDxHealth SA 11.8. Exact Sciences Corporation 11.9. Illumina Inc. 11.10. Sysmex Inostics 11.11. Bio-Rad Laboratories, Inc. 11.12. Biocept, Inc. 11.13. NeoGenomics, Inc. 11.14. ANGLE plc. 11.15. Menarini-Silicon Biosystems 11.16. Vortex Biosciences, Inc. 11.17. Exosome Diagnostics, Inc. 11.18. Agena Bioscience, Inc. 11.19. MedGenome Inc. 11.20. Epigenomics AG 11.21. Personal Genome Diagnostics, Inc. 12. Key Findings 13. Industry Recommendations